PetIQ Inc (NASDAQ:PETQ) Forecasted to Post FY2018 Earnings of $0.78 Per Share
PetIQ Inc (NASDAQ:PETQ) – Equities research analysts at SunTrust Banks boosted their FY2018 EPS estimates for PetIQ in a note issued to investors on Tuesday, November 13th, Zacks Investment Research reports. SunTrust Banks analyst W. Chappell now expects that the company will post earnings of $0.78 per share for the year, up from their prior estimate of $0.77. SunTrust Banks has a “Buy” rating and a $40.00 price target on the stock. SunTrust Banks also issued estimates for PetIQ’s Q3 2019 earnings at $0.33 EPS, Q4 2019 earnings at $0.18 EPS and FY2019 earnings at $0.94 EPS.
Several other equities research analysts also recently issued reports on the stock. CL King began coverage on shares of PetIQ in a research note on Friday, September 28th. They set a “buy” rating and a $49.00 price objective for the company. Raymond James restated a “buy” rating and set a $45.00 price target (up previously from $33.00) on shares of PetIQ in a research report on Wednesday, September 19th. BidaskClub downgraded shares of PetIQ from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 15th. Jefferies Financial Group reissued a “buy” rating on shares of PetIQ in a research report on Friday, August 24th. Finally, Oppenheimer increased their price objective on PetIQ from $28.00 to $50.00 and gave the stock an “outperform” rating in a report on Friday, October 5th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $41.83.
PetIQ (NASDAQ:PETQ) last issued its quarterly earnings data on Tuesday, November 13th. The company reported $0.47 EPS for the quarter, topping the consensus estimate of $0.25 by $0.22. The firm had revenue of $131.40 million for the quarter, compared to analyst estimates of $125.22 million. PetIQ had a negative net margin of 0.12% and a positive return on equity of 11.68%. The business’s revenue for the quarter was up 116.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.30 EPS.
In other PetIQ news, insider Will Santana sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 18th. The stock was sold at an average price of $42.02, for a total value of $840,400.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Ecp Helios Partners Iv, L.P. sold 1,838,836 shares of the business’s stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $37.15, for a total value of $68,312,757.40. The disclosure for this sale can be found here. Insiders have sold a total of 3,004,503 shares of company stock valued at $111,078,941 over the last 90 days. Corporate insiders own 45.26% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Rehmann Capital Advisory Group bought a new stake in shares of PetIQ during the 3rd quarter worth $55,000. Harvest Fund Management Co. Ltd acquired a new stake in PetIQ during the third quarter worth approximately $135,000. The Manufacturers Life Insurance Company grew its stake in PetIQ by 64.0% during the first quarter. The Manufacturers Life Insurance Company now owns 6,838 shares of the company’s stock worth $182,000 after purchasing an additional 2,669 shares during the period. Zions Bancorporation acquired a new stake in PetIQ during the third quarter worth approximately $187,000. Finally, Advisory Services Network LLC boosted its holdings in PetIQ by 296.0% in the third quarter. Advisory Services Network LLC now owns 4,950 shares of the company’s stock worth $195,000 after acquiring an additional 3,700 shares in the last quarter. Hedge funds and other institutional investors own 78.45% of the company’s stock.
PetIQ Company Profile
PetIQ, Inc operates as a pet health and wellness company. It provides veterinarian services and veterinarian-grade pet products, including prescription (Rx) medications, over-the-counter (OTC) flea and tick preventatives, and health and wellness products for dogs and cats. The company offers pet prescription medications, including products for arthritis, thyroid, and diabetes and pain treatments, as well as heartworm preventatives, antibiotics, and other specialty medications; over-the-counter medications and supplies, such as flea and tick control products in various forms comprising spot on treatments, chewables, and collars; and health and wellness products consisting of specialty treats and other pet products, which include dental treats and nutritional supplements.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.